Sanofi (NASDAQ:SNY) Stock Has Average Target Price of $53.00 According to Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Sanofi: 12 of 21 covering firms rate it Hold, eight Buy, and one Strong Buy. Their average 12-month price target is $53.
• Sanofi reported quarterly EPS of $2.04, beating the $1.56 consensus estimate, and revenue of $17.25 billion versus the $14.30 billion estimate. Revenue rose 16.2% year over year.
• Shares opened at $48.23, within the stock’s 52-week range of $39.07 to $52.68.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-one research firms that are covering the firm, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $53.00.

Several analysts have recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Sanofi in a research report on Tuesday, September 29th. HSBC reiterated a "buy" rating on shares of Sanofi in a research report on Thursday, September 10th. Royal Bank Of Canada assumed coverage on Sanofi in a research note on Tuesday, September 8th. They set a "sector perform" rating on the stock. Sanford C. Bernstein restated a "buy" rating on shares of Sanofi in a research report on Monday, August 3rd. Finally, Berenberg Bank restated a "buy" rating on shares of Sanofi in a research report on Monday, October 5th.

Hedge Funds Weigh In On Sanofi

Several large investors have recently modified their holdings of the stock. Tidal Investments LLC boosted its stake in Sanofi by 21.5% during the second quarter. Tidal Investments LLC now owns 165,289 shares of the company's stock worth $7,051,000 after buying an additional 29,283 shares during the period. Archford Capital Strategies LLC purchased a new stake in shares of Sanofi in the second quarter valued at $1,417,000. Mondrian Investment Partners LTD raised its stake in shares of Sanofi by 2.3% in the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company's stock valued at $233,038,000 after acquiring an additional 129,575 shares during the period. Assetmark Inc. raised its stake in shares of Sanofi by 14.8% in the first quarter. Assetmark Inc. now owns 509,464 shares of the company's stock valued at $24,546,000 after acquiring an additional 65,796 shares during the period. Finally, AMG National Trust Bank bought a new stake in shares of Sanofi in the 1st quarter worth about $2,719,000. Institutional investors own 14.03% of the company's stock.

Sanofi Price Performance

Sanofi stock opened at $48.23 on Wednesday. The company has a market cap of $116.93 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.32 and a beta of 0.31. The firm's fifty day moving average is $42.44 and its 200 day moving average is $44.36. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a 52-week low of $39.07 and a 52-week high of $52.68.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same quarter last year, the business earned $2.91 earnings per share. Sanofi's quarterly revenue was up 16.2% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.